On Friday, Glenmark Pharmaceutical said that it has got final approval from the US health regulator for Voriconazole Tablets that is used for treating fungal infections.

Glenmark said in a BSE filing, “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US Food & Drug Administration (USFDA) for Voriconazole Tablets, the therapeutic equivalent to Vfend tablets.”

The approval is granted for tablets in 50 mg and 200 mg strengths.

Get accurate advice on share market investment